YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
Fujihara M, Shien T, Shien K, Suzawa K, Takeda T, Zhu Y, Mamori T, Otani Y, Yoshioka R, Uno M, Suzuki Y, Abe Y, Hatono M, Tsukioki T, Takahashi Y, Kochi M, Iwamoto T, Taira N, Doihara H, Toyooka S.
Fujihara M, et al. Among authors: zhu y.
Int J Mol Sci. 2021 Nov 26;22(23):12809. doi: 10.3390/ijms222312809.
Int J Mol Sci. 2021.
PMID: 34884609
Free PMC article.